Alcoholic Hepatitis Pipeline Insights 2024: Emerging Therapies and Market Prospects
The global fight against Alcoholic Hepatitis (AH) is witnessing significant progress, with over 10 key companies actively developing more than 10 treatment therapies. The "Alcoholic Hepatitis Pipeline Insight, 2024" report by DelveInsight offers a detailed analysis of the current clinical development landscape and growth prospects within the Alcoholic Hepatitis market.
Key Developments:
- Breakthrough Therapy Designation: In May 2024, DURECT Corporation announced that the U.S. FDA granted Breakthrough Therapy designation to larsucosterol for treating severe alcohol-associated hepatitis, marking a pivotal moment in AH treatment.
- Aldeyra Therapeutics' Progress: January 2024 saw Aldeyra Therapeutics making strides with its RASP modulator platform, including plans for a Phase 2 clinical trial expansion of ADX-629 in Sjögren-Larsson Syndrome and initiating a Phase 2 trial in moderate alcoholic hepatitis.
- AHFIRM Trial Results: DURECT Corporation revealed topline results from its AHFIRM trial in November 2023, evaluating the safety and efficacy of larsucosterol in 307 patients with severe AH.
Emerging Therapies: The pipeline includes promising therapies such as Burfiralimab by ImmuneMed, NP-011 by NEXEL, SZN 043 by Surrozen, SRT-015 by Seal Rock Therapeutics, INT 787 by Intercept Pharmaceuticals, ADX 629 by Aldeyra Therapeutics, and Canakinumab by Novartis Pharmaceuticals.
Therapeutic Assessment: The report categorizes products by Route of Administration (Intravenous, Subcutaneous, Oral, Intramuscular) and Molecule Type (Monoclonal antibody, Small molecule, Peptide), providing a comprehensive therapeutic assessment.
Market Dynamics: The Alcoholic Hepatitis market is driven by the increasing prevalence of alcohol-related diseases and the development of new treatment strategies. However, challenges such as the lack of therapies for severe AH and disease complications hinder market growth.
Conclusion: The Alcoholic Hepatitis Pipeline report is an essential resource for understanding the current and future landscape of AH treatment, offering insights into clinical trials, therapeutic developments, and market dynamics.